ClinicalTrials.gg
Not yet recruitingNCT07351591Updated Jan 20, 2026

A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers

A Phase 2 interventional study of Organoid Drug Sensitivity Testing-Guided Therapy in Advanced Biliary Tract Cancer(BTC), sponsored by Eastern Hepatobiliary Surgery Hospital. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Eastern Hepatobiliary Surgery Hospital · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a prospective, non-randomized, open-label, single-center phase II clinical trial. It aims to evaluate the efficacy and feasibility of using patient-derived tumor organoid drug sensitivity testing (ODST) to guide personalized systemic therapy for patients with unresectable biliary tract cancers (BTC). A total of 88 eligible patients will be enrolled and grouped based on patient preference into either the ODST-guided group or the control group (standard therapy). Tumor tissues obtained via biopsy will be used to establish organoid cultures. Drug sensitivity testing will be performed on a panel of approved regimens (including GC, GEMOX, Durvalumab+GC, Pembrolizumab+GC, and Toripalimab+Lenvatinib+GEMOX) to identify the most effective treatment. Patients for whom organoid testing fails or results are unavailable within one month will receive standard therapy. The primary endpoints are Objective Response Rate (ORR) and Progression-Free Survival (PFS). Secondary endpoints include Overall Survival (OS) and safety profiles. The study seeks to provide a novel, personalized treatment strategy to improve outcomes for patients with advanced BTC.

Read the detailed description
  1. Study Design:

    This is a single-center, prospective, non-randomized, open-label, controlled phase II clinical trial conducted at the Third Affiliated Hospital of Naval Medical University.

  2. Study Population:

    The study will enroll 88 adult patients (aged 18-70) with unresectable biliary tract cancers, confirmed per NCCN guidelines. Participants must have an ECOG performance status of 0-1, a life expectancy of >12 weeks, and adequate organ function.

  3. Interventions:

    Organoid Drug Sensitivity Testing (ODST) Group: Tumor tissue from biopsies is used to establish patient-derived organoids. Successful organoids undergo drug sensitivity testing against a predefined panel of regimens. The most effective drug(s), based on IC50 and AUC values, are recommended for treatment.

    Control Group (Standard Therapy): Patients receive physician's choice of standard systemic therapy, including GC, GEMOX, or other approved regimens.

  4. Study Endpoints:

    Primary Endpoints:

    Objective Response Rate (ORR) as assessed by RECIST 1.1.

    Progression-Free Survival (PFS).

    Secondary Endpoints:

    Overall Survival (OS).

    Safety and tolerability, assessed by the incidence and severity of adverse events (AEs, SAEs) according to NCI CTCAE v5.0.

  5. Follow-up:

    Patients will be followed regularly with imaging assessments every 42 days (±3 days) for the first 48 weeks, and every 63 days (±3 days) thereafter. Laboratory tests and clinical evaluations will be conducted to monitor treatment response and adverse events until death, withdrawal of consent, or study termination.

  6. Statistical Analysis:

Sample size was calculated based on an assumed improvement in ORR from 26.7% in the control group to 66.7% in the ODST-guided group (α=0.05, power=80%, 1:1 allocation, 10% dropout rate). Statistical analyses will be performed using SAS, with descriptive statistics for safety and efficacy analyses.

02

Conditions studied

  • Advanced Biliary Tract Cancer(BTC)

Keywords

  • organoid
  • drug-sensitive test
03

In context

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

This study's planned enrollment of 88 is above the median of 58 across 429 interventional studies indexed under Biliary Tract Neoplasms.

Browse Biliary Tract Neoplasms studies →

Lead sponsor

Eastern Hepatobiliary Surgery Hospital is the lead sponsor of 69 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged between 18 and 70 years (inclusive).
  2. Diagnosis of biliary tract confirmed according to the NCCN Clinical Practice Guidelines.
  3. The subject or their legal guardian understands and voluntarily signs the Form, and is willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures as required by the protocol.
  4. The subject is not a candidate for curative resection, transplantation, or local ablation therapy. This includes patients with recurrent disease after prior radical therapy who are not eligible for further curative resection or ablation.
  5. of at least 12 weeks.
  6. No radiotherapy within 12 weeks prior to the first dose of the study drug.
  7. Liver function classified as Class A or Class B with a score of 7.
  8. (ECOG) Performance Status of 0 or 1.
  9. Adequate organ and bone marrow function, defined by the following laboratory values within 7 days prior to randomization (without receiving any blood transfusions, hematopoietic growth factors, albumin, or other corrective drugs within 14 days prior to the laboratory tests):

    9.1. Hematological:

    • (ANC) ≥ 1.5 × 10⁹/L
    • count (PLT) ≥ 75 × 10⁹/L
    • (HGB) ≥ 9.0 g/dL 9.2. Hepatic:
    • Total (TBIL) ≤ 3 × (ULN)
    • (ALT), Aspartate Aminotransferase (AST), and Alkaline Phosphatase (ALP) ≤ 5 × ULN
    • Serum Albumin ≥ 28 g/L 9.3. Renal:
    • Serum Creatinine (Cr) ≤ 1.5 × ULN or (CCr) ≥ 50 mL/min (calculated using the Cockcroft-Gault formula)
    • Urinalysis indicates urine protein \< 2+; if baseline urinalysis shows urine protein ≥ 2+, a 24-hour urine collection must demonstrate 24-hour urine protein quantification \< 1 g.

    9.4. Coagulation:

    * (INR) and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN

  10. For women of (WOCBP), a negative urine or serum pregnancy test must be confirmed within 3 days prior to the first dose of study drug (Cycle 1, Day 1). If a urine test is inconclusive, a serum pregnancy test is required. WOCBP and male subjects must agree to use adequate during the observation period and for at least 8 weeks after the last dose of the study drug. A woman is considered not of childbearing potential if she is (≥1 year without menses) or has undergone surgical sterilization (bilateral oophorectomy, hysterectomy, or bilateral tubal ligation). Subjects (both male and female) with risk of pregnancy must use highly effective contraception (with a failure rate of \<1% per year) during the entire treatment period and for 120 days after the last dose of the study drug (or 180 days after the last dose of chemotherapy agents).

Exclusion criteria

Exclusion Criteria:

  1. Uncorrectable coagulopathy or individuals with a significant bleeding tendency.
  2. Evidence of any concurrent malignant disease.
  3. Diagnosis of another within 3 years prior to the first dose, except for radically treated cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, and/or carcinoma in situ that has undergone curative resection.
  4. Patients requiring long-term anticoagulant or antiplatelet therapy that cannot be discontinued.
  5. Presence of hepatic encephalopathy or pleural effusion/ascites requiring therapeutic intervention.
  6. Other anti-tumor or systemic therapies within 2 weeks prior to enrollment:

    • Treatment with Chinese herbal medicine with demonstrated anti-tumor properties.
    • Treatment with Chinese herbal medicine with anti-tumor indications or drugs with immunomodulatory effects (including thymosin, interferon, interleukin), except for localized use to control pleural effusion.
  7. History of systemic treatment for active disease or ongoing therapy:

    • Active autoimmune disease requiring systemic treatment (e.g., disease-modifying drugs, , or immunosuppressants) within 2 years prior to the first dose. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement for adrenal or pituitary insufficiency) is not considered systemic treatment.
    • Systemic corticosteroid therapy (excluding topical, intranasal, inhaled, or other local routes) or any other form of immunosuppressive therapy within 7 days prior to the first study dose. The use of physiologic doses of corticosteroids (≤10 mg/day prednisone or equivalent) is permitted.
  8. Severe hepatic or renal insufficiency.
  9. Presence of any severe or uncontrolled systemic disease, including but not limited to:

    • , poorly controlled resting abnormalities (e.g., complete left bundle branch block, second-degree or higher atrioventricular block, ventricular arrhythmia, or atrial fibrillation).
    • Unstable angina, congestive heart failure ( (NYHA) Class ≥ II).
    • Myocardial infarction within 6 months prior to randomization.
    • History of esophageal or gastric variceal bleeding within 6 months prior to enrollment.
    • Poorly controlled hypertension (systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg).
    • History of non-infectious pneumonitis requiring corticosteroid treatment within 1 year prior to the first dose, or current clinically active interstitial lung disease.
    • Active tuberculosis.
    • Active or uncontrolled infection requiring systemic therapy.
    • Clinically active diverticulitis, intra-abdominal abscess, or gastrointestinal obstruction.
    • Decompensated liver disease, acute or chronic active hepatitis.
    • Unstable or active peptic ulcer disease, or patients with gastrointestinal bleeding.
    • Poorly controlled diabetes mellitus (fasting blood glucose >10 mmol/L).
    • Urinalysis indicating urine protein ≥ ++ and confirmed 24-hour urine protein quantification >1.0 g.
    • Uncontrolled hypercalcemia (>1.5 mmol/L ionized calcium, or calcium >12 mg/dL, or corrected serum calcium > ), or symptomatic hypercalcemia requiring continued bisphosphonate therapy.
    • Non-healing wound(s) or fracture(s).
    • Psychiatric disorder that compromises the ability to comply with the treatment protocol.
  10. Female subjects who are pregnant or breastfeeding.
  11. Assessed by the investigator as being unable or unwilling to comply with the requirements of the study protocol.
  12. Known allergy to any of the study drug(s) used in this trial.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    Arm 1

    Physician's Choice Group:According to empirical and clinical practice

    Drug: Organoid Drug Sensitivity Testing-Guided Therapy

Interventions

  • DrugOrganoid Drug Sensitivity Testing-Guided Therapy

    Fresh tumor tissue from resection is used to establish and culture patient-derived organoids. Successful organoids undergo drug sensitivity testing against a predefined panel of drugs (Gemcitabine + Cisplatin,Gemcitabine + Oxaliplatin,Durvalumab + Gemcitabine + Cisplatin,Pembrolizumab + Gemcitabine + Cisplatin,Toripalimab + Lenvatinib + Gemcitabine + Oxaliplatin). The most effective drug(s), based on IC50 and AUC values, are recommended for treatment

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., LenvatinibStudies of LenvatinibLenvatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., DurvalumabStudies of DurvalumabDurvalumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate(ORR)

    ORR was assessed by investigators per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

    Time frame: Through out the study (up to 3 years)

  2. Progression-free Survival(PFS)

    In treated subjects, the time from first recording to tumor progression (based on RECIST 1.1 and mRECIST) or death from any cause.

    Time frame: up to 3 years

Secondary outcomes

  1. Overall Survival(OS)

    Time frame: Up to 3 years

  2. Adverse event

    Time frame: From the date of each patient's enrollment until 30 days (±7 days) after the last dose of study drug or until the initiation of new anti-tumor therapy, whichever occurs first.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Oct 2026, 9 months later.

Of 101 non-industry phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 60. This study's planned 9 months is below that.

Counting every sponsor, half of 132 studies reached it within 39 months; a quarter within 29 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2026
First posted
Jan 20, 2026
StartEst.
Jan 30, 2026
Primary completionEst.
Oct 30, 2026
CompletionEst.
Dec 31, 2027
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07351591
Lead sponsor
Eastern Hepatobiliary Surgery Hospital
Responsible party
Shen Feng (Professor, Eastern Hepatobiliary Surgery Hospital) — Principal investigator
First posted
Jan 20, 2026
Start date
Jan 30, 2026 (estimated)
Primary completion
Oct 30, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 20, 2026

Study contacts

Kui Wang
Contact
wangkuiykl@163.com
+8613636330827
Feng Shen
principal investigator · Eastern Hepatobiliary Surgery Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion